Journal Article

Potential Role of Tumor-Derived Exosomes in Non-Small-Cell Lung Cancer in the Era of Immunotherapy

Tartarone, Alfredo, Lerose, Rosa, Tartarone, Marina, Aieta, Michele

2022

Overview

Lung cancer, of which non-small-cell lung cancer (NSCLC) represents about 80% of all cases, is the second most common cancer diagnosed in the general population and one of the major causes of cancer-related deaths worldwide. Overall, the outcomes of patients with advanced NSCLC are still disappointing despite advances in diagnosis and treatment. In recent years immune-checkpoint inhibitors (ICIs), administered alone or in combination with chemotherapy, have revolutionized the treatment landscape of patients with advanced non-small-cell lung cancer. However, until now, tissue expression of PD-L1 and tumor mutation burden represent the only available biomarkers for NSCLC patients treated with ICIs. A growing body of evidence showed that tumor-derived exosomes (TDEs) have the PD-L1 protein on their surface and that they are involved in angiogenesis, tumor growth, invasion, metastasis and immune escape. This review focused on the potential clinical applications of TDEs in NSCLC, including their possible role as a biomarker for prognosis and disease monitoring in patients undergoing immunotherapy.

• Publisher: MDPI AG,MDPI
• Subject: Angiogenesis / Apoptosis / B cells / Biological products / Biomarkers / Biopsy / Cancer / Cancer therapies / Care and treatment / Cell organelles / Chemotherapy / Drug therapy / Exosomes / Health aspects / Health services / Immune checkpoint inhibitors / Immune system / Immunotherapy / L1 protein / Ligands / Lipids / liquid biopsy / Lung cancer / Lung cancer, Non-small cell / Medical research / Melanoma / Metastases / Metastasis / Methods / MicroRNAs / Monoclonal antibodies / Mutation / Non-small cell lung carcinoma / non-small-cell lung cancer / Patients / PD-L1 protein / Physiology / Proteins / Review / Small cell lung carcinoma / tumor-derived exosomes / Tumors